Tanya L Applegate

List of Publications by Year
in descending order

85 papers	3,121 citations	186209 28 h-index	175177 52 g-index
85 all docs	85 docs citations	85 times ranked	3752 citing authors

#	Article	IF	Citations
1	Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review. Journal of Infectious Diseases, 2022, 226, 1005-1021.	1.9	24
2	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Reports, 2022, 4, 100462.	2.6	10
3	Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. Clinical Infectious Diseases, 2021, 72, 1392-1400.	2.9	26
4	Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingerstick Capillary Dried Blood Spot and Venepuncture-Collected Samples. Journal of Infectious Diseases, 2021, 223, 818-826.	1.9	7
5	Evaluation of Hepatitis C Virus Core Antigen Assay in a Resource-Limited Setting in Pakistan. Diagnostics, 2021, 11, 1354.	1.3	5
6	Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment ofÂrecently acquired hepatitis C infection. Journal of Hepatology, 2021, 75, 829-839.	1.8	27
7	Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study. Clinical Infectious Diseases, 2020, 71, 1502-1510.	2.9	46
8	Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs preâ€and postâ€universal access to directâ€acting antiviral treatment in Australia: The LiveRLife study. Journal of Viral Hepatitis, 2020, 27, 281-293.	1.0	39
9	Modeling based response guided therapy in subjects with recent hepatitis C infection. Antiviral Research, 2020, 180, 104862.	1.9	6
10	Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. Journal of Infectious Diseases, 2020, 222, S758-S772.	1.9	15
11	Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLOâ€€): An openâ€label, singleâ€arm, phase 4, multicentre trial. Health Science Reports, 2020, 3, e151.	0.6	4
12	Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis. Journal of Infectious Diseases, 2020, 221, 2043-2049.	1.9	16
13	Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study. Journal of Viral Hepatitis, 2019, 26, 1423-1430.	1.0	12
14	Performance evaluation of the Hologic Aptima HCV Quant Dx assay for detection of HCV RNA from dried blood spots. Journal of Clinical Virology, 2019, 112, 40-44.	1.6	16
15	Hepatitis C virus testing, liver disease assessment and directâ€acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study. Journal of Viral Hepatitis, 2019, 26, 969-979.	1.0	25
16	Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. Infection, Genetics and Evolution, 2019, 71, 36-41.	1.0	14
17	A latent class approach to identify multiâ€risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015. Journal of the International AIDS Society, 2019, 22, e25222.	1.2	6
18	Genomic variability of withinâ€host hepatitis C variants in acute infection. Journal of Viral Hepatitis, 2019, 26, 476-484.	1.0	6

#	Article	IF	Citations
19	A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections. Infection, Genetics and Evolution, 2019, 69, 76-84.	1.0	6
20	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2019, 4, 135-184.	3.7	370
21	Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent <scp>HCV</scp> genotype 1 infection. Journal of Viral Hepatitis, 2018, 25, 1180-1188.	1.0	25
22	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 153-161.	3.7	231
23	Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay. Journal of Infectious Diseases, 2018, 217, 1889-1896.	1.9	88
24	HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype. Journal of Medical Virology, 2018, 90, 120-130.	2.5	6
25	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. International Journal of Drug Policy, 2018, 62, 14-23.	1.6	58
26	Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. International Journal of Drug Policy, 2018, 61, 23-30.	1.6	57
27	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. International Journal of Drug Policy, 2018, 62, 94-103.	1.6	22
28	Hepatitis C Virus Diagnosis and the Holy Grail. Infectious Disease Clinics of North America, 2018, 32, 425-445.	1.9	52
29	Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples. Journal of Molecular Diagnostics, 2018, 20, 621-627.	1.2	17
30	Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. Infection, Genetics and Evolution, 2017, 49, 88-96.	1.0	8
31	Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment. Scientific Reports, 2017, 7, 41719.	1.6	12
32	IFN-Î»3, not IFN-Î»4, likely mediates IFNL3â€“IFNL4 haplotypeâ€“dependent hepatic inflammation and fibrosis. Nature Genetics, 2017, 49, 795-800.	9.4	86
33	Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. The Lancet Gastroenterology and Hepatology, 2017, 2, 514-520.	3.7	123
34	Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. Journal of Clinical Virology, 2017, 92, 32-38.	1.6	32
35	<scp>HCV</scp> reinfection incidence among individuals treated for recent infection. Journal of Viral Hepatitis, 2017, 24, 359-370.	1.0	68
36	Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. International Journal of Drug Policy, 2017, 47, 177-186.	1.6	13

#	Article	IF	Citations
37	Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. Expert Review of Molecular Diagnostics, 2017, 17, 1109-1115.	1.5	116
38	Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC Infectious Diseases, 2017, 17, 420.	1.3	6
39	Phylogenetic analysis of fullâ€length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC³ Study. Journal of Viral Hepatitis, 2017, 24, 43-52.	1.0	14
40	Analysis of resistanceâ€associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents. Journal of Viral Hepatitis, 2017, 24, 37-42.	1.0	11
41	A molecular transmission network of recent hepatitis C infection in people with and without <scp>HIV</scp>: Implications for targeted treatment strategies. Journal of Viral Hepatitis, 2017, 24, 404-411.	1.0	23
42	Sequencing of hepatitis C virus for detection of resistance to directâ€acting antiviral therapy: A systematic review. Hepatology Communications, 2017, 1, 379-390.	2.0	26
43	Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection. Liver International, 2016, 36, 1774-1782.	1.9	8
44	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. Antiviral Therapy, 2016, 21, 465-465.	0.6	5
45	Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. Journal of Hepatology, 2016, 64, 1247-1255.	1.8	18
46	Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. Journal of Infectious Diseases, 2016, 214, 1383-1389.	1.9	16
47	Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DAREâ€C II study. Hepatology, 2016, 64, 1911-1921.	3.6	50
48	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. Antiviral Therapy, 2016, 21, 425-434.	0.6	6
49	Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. Virology Journal, 2016, 13, 32.	1.4	10
50	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology, 2016, 64, 34-46.	3.6	83
51	HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection. BMC Infectious Diseases, 2016, 16, 241.	1.3	5
52	HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection. Infection, Genetics and Evolution, 2016, 37, 252-258.	1.0	13
53	Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men. PLoS ONE, 2016, 11, e0162002.	1.1	8
54	Naturally Occurring Dominant Drug Resistance Mutations Occur Infrequently in the Setting of Recently Acquired Hepatitis C. Antiviral Therapy, 2015, 20, 199-208.	0.6	21

#	Article	IF	Citations
55	Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study. PLoS ONE, 2015, 10, e0122232.	1.1	41
56	Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada. Drug and Alcohol Dependence, 2015, 152, 272-276.	1.6	29
57	Interferon Î» 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types. Journal of Molecular Diagnostics, 2015, 17, 583-589.	1.2	3
58	A molecular phylogenetics-based approach for identifying recent hepatitis C virus transmission events. Infection, Genetics and Evolution, 2015, 33, 101-109.	1.0	23
59	A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs. Journal of Epidemiology and Community Health, 2015, 69, 745-752.	2.0	21
60	Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC³ study. Journal of Viral Hepatitis, 2015, 22, 708-717.	1.0	13
61	Mixed HCV infection and reinfection in people who inject drugsâ€"impact on therapy. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 218-230.	8.2	79
62	A Comparison of Seminal Hepatitis C Virus (HCV) RNA Levels During Recent and Chronic HCV Infection in HIV-Infected and HIV-Uninfected Individuals. Journal of Infectious Diseases, 2015, 211, 736-743.	1.9	30
63	The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis. PLoS ONE, 2015, 10, e0131437.	1.1	48
64	Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. Hepatology, 2014, 60, 1571-1580.	3.6	59
65	A Quantitative Comparison of Anti-HIV Gene Therapy Delivered to Hematopoietic Stem Cells versus CD4+ T Cells. PLoS Computational Biology, 2014, 10, e1003681.	1.5	15
66	Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study. Journal of Clinical Virology, 2014, 61, 430-434.	1.6	8
67	Dynamics of HCV RNA levels during acute hepatitis C virus infection. Journal of Medical Virology, 2014, 86, 1722-1729.	2.5	26
68	Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology, 2013, 57, 2124-2134.	3.6	61
69	Sequencing of the Hepatitis C Virus: A Systematic Review. PLoS ONE, 2013, 8, e67073.	1.1	25
70	Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection. PLoS ONE, 2013, 8, e80003.	1.1	9
71	Virological responses during treatment for recent hepatitis C virus. Aids, 2012, 26, 1653-1661.	1.0	27
72	Multiple shRNA combinations for near-complete coverage of all HIV-1 strains. AIDS Research and Therapy, 2011, 8, 1.	0.7	33

#	Article	IF	Citations
73	Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology, 2010, 52, 1216-1224.	3.6	156
74	In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy. Retrovirology, 2010, 7, 83.	0.9	16
75	Towards a Clinically Relevant Lentiviral Transduction Protocol for Primary Human CD34+ Hematopoietic Stem/Progenitor Cells. PLoS ONE, 2009, 4, e6461.	1.1	44
76	96 shRNAs designed for maximal coverage of HIV-1 variants. Retrovirology, 2009, 6, 55.	0.9	38
77	Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success. Virology Journal, 2009, 6, 184.	1.4	19
78	An Infinitely Expandable Cloning Strategy plus Repeat-Proof PCR for Working with Multiple shRNA. PLoS ONE, 2008, 3, e3827.	1.1	12
79	Non-Oxidative Metabolism of Ethanol by Rat Pancreatic Acini. Pancreatology, 2004, 4, 82-89.	0.5	45
80	Diagnosis and Molecular Monitoring of Acute Promyelocytic Leukemia Using DzyNA Reverse Transcription-PCR to Quantify PML/RARÎ± Fusion Transcripts. Clinical Chemistry, 2002, 48, 1338-1343.	1.5	9
81	Factors That Influence Deoxyribozyme Cleavage during Polymerase Chain Reaction. Analytical Biochemistry, 2000, 286, 300-303.	1.1	4
82	DzyNA-PCR: Use of DNAzymes to Detect and Quantify Nucleic Acid Sequences in a Real-Time Fluorescent Format. Clinical Chemistry, 2000, 46, 625-630.	1.5	83
83	Metabolism of ethanol by rat pancreatic acinar cells. Translational Research, 1998, 132, 294-302.	2.4	87
84	The effect of ethanol on pancreatic enzymesâ€“a dietary artefact?. Biochimica Et Biophysica Acta - General Subjects, 1998, 1379, 314-324.	1.1	19
85	Rapid Ca2+ influx induced by the action of dibutylhydroquinone and glucagon in the perfused rat liver. Biochemical Journal, 1997, 323, 463-467.	1.7	22